A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects

Next Previous
Trial Profile

A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2016

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 16 Oct 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top